Navigation Links
Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
Date:3/3/2008

Phase 2b Trial to Examine Safety and Efficacy of DARA versus Active Control

PRINCETON, N.J., March 3 /PRNewswire-FirstCall/ -- Pharmacopeia (Nasdaq: PCOP), an innovator in the discovery and development of novel small molecule therapeutics, today announced the initiation of a Phase 2b clinical study of PS433540, the company's lead internal product candidate. This randomized, double-blind, placebo and active-controlled, parallel-group study is designed to evaluate the compound's safety and efficacy at three different doses in subjects with Stage 1 and Stage 2 hypertension.

After a lead-in period, the multi-center trial is expected to randomize approximately 375 subjects into five study arms receiving PS433540 (200 mg, 400 mg or 800 mg); irbesartan (300 mg), an angiotensin II receptor antagonist; or placebo. All doses will be administered once daily for 12 weeks. The trial's primary objective is to compare the change from baseline in mean seated systolic blood pressure for each dose of PS433540 with placebo. Additional study objectives include comparisons of changes in blood pressure for each dose of PS433540 with irbesartan.

"We are pleased with the DARA program's rapid progress. This is our second Phase 2 study of PS433540 in hypertensive patients to provide key indications of the compound's therapeutic potential," said Les Browne, Ph.D., President and Chief Executive Officer of Pharmacopeia. "We look forward to the completion of this study by the end of 2008 as well as the reporting of results from our on-going Phase 2a trial in the second quarter of 2008."

Pharmacopeia recently completed enrollment in its ongoing Phase 2a trial of PS433540 in patients with Stage 1 and Stage 2 hypertension. Results from that study
'/>"/>

SOURCE Pharmacopeia
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Pharmacopeia Completes Enrollment in Phase 2 Hypertension Study with PS433540 (DARA)
2. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
3. Pharmacopeia to Present at BIO CEO & Investor Conference 2008
4. Pharmacopeia Announces Additional Positive Findings from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
5. Pharmacopeia Announces Third Quarter 2007 Financial Results
6. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
7. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
8. Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
11. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...wswire/ -- Reportlinker.com announces that a new m...e: ,, Inflammatory Disorders: Therapies That S...p://www.reportlinker.com/p0165600/Inflammatory-Dis...ne-Response.html ,, The human immune system ca...producing an exaggerated response to a foreign sub...
(Date:11/30/2009)... According to Millennium Research ...ology market intelligence, the nearly $1.2 billion...t 5% over 2008 as patients chose to delay or foreg...e market will, however, begin recovery in 2010, an... growth rates of over 15%. MRG,s facial injectable...
(Date:11/30/2009)... 30 Today at the 95th Scientific A...ociety of North America (RSNA), Bayer HealthCare P...e first patient in an international Phase III clin...florbetaben (BAY 94-9172) PET imaging in the detec...re a pathological hallmark of Alzheimer,s disease....
Breaking Medicine Technology:Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 2Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 3Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 4Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response 5Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 2Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimer's Disease 3Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 1Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 2Kaiser Permanente Debuts New Ads Focused on Technology and Innovation 55897 3Employers Launch Grassroots Health Reform Coalition 55895 1Employers Launch Grassroots Health Reform Coalition 55895 2Employers Launch Grassroots Health Reform Coalition 55895 3Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 1Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 2Monsanto Licenses Use of Cellectis Innovative Genome Modification Technology 13776 3
...,(Nasdaq: ACEL ) today announced it has confirmed...ccurred in the Phase IIIb clinical trial of its le...ts with unresectable,malignant mesothelioma. The n...company learned that total events in the study had...lan for the study, the company must wait,until 316...
...urnal of the American Medical ... widely used to treat type 2,diabetes has been fou...ardial infarction) or stroke when used alone or in...cording to a Cleveland Clinic study. The study pu...e,American Medical Association reports that use of...
Other Medicine Technology:Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program 2Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program 3Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure 2Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure 3
(Date:11/30/2009)... , NEW YORK, Nov. 30 Report...port is available in its catalogue: ,, Key Pla...merging strategies in ingredients, pharma, food an...649/Key-Players-and-Innovative-Start-Ups-in-Nutrac...-food-and-drinks.html ,, Nutraceuticals are bi...
(Date:11/30/2009)..., WASHINGTON, Nov. 30 - Salon Leau...e" on Monday, December 7(th) to raise funds and cr...d terminal diseases. All proceeds from each haircu...n,s Research Hospital. ,, Salon Leau has been ...e salon is owned by LoAnn Lai, widely recognized f...
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 /PRNewswire/ -...about gifts for the holidays. For a loved one with...mily members and friends oftentimes struggle with ...ving , one of the leading providers of senior livi...s and dementia care , offers these suggestions. ,...
(Date:11/30/2009)..., CHICAGO, Nov. 30 Physicians at...orted today on results of a study demonstrating th...angiography (cCTA) by Rcadia,s COR Analyzer System...tery stenosis in hospital emergency department (ED...tomated system to enhance the use of cCTA has pote...
(Date:11/30/2009)...ONovember 30, 2009A pet owner knows the enormous j...lly in troubled times. Most pets are considered im...mpanions. A growing body of research now documents...opment, elderly care, mental illness, physical imp...the rehabilitation of incarcerated youth and adult...
Breaking Medicine News(10 mins):Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 2Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 3Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 4Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 5Health News:Reportlinker Adds Key Players and Innovative Start-Ups in Nutraceuticals: Emerging Strategies in Ingredients, Pharma, Food and Drinks 6Health News:Georgetown Hair Salon Helps St. Jude Find A Cure 2Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:The therapeutic benefits of the human-animal bond 2
... have found that even a two-minute delay in severi...on //reserves and offset anemia for months. I...oor nations. It is a problem particularly in devel... be reversible, even with iron treatments. ...
... has urged the doctors working in various hospital...nti-rabies vaccine, as recommended by World Health...said that by following the intra-dermal route, the...sociation had taken the decision in view of increa...
... nearly 24% of all diseases in adults and 33% of d...O) said // that all this can be prevented by livin...ensively seen in developing countries and could be...tory infections, various forms of accidental injur...
...e afro American women should be first vaccinated a...s recently approved by the FDA //. This was publi...researchers at The Miriam Hospital and Brown Medic...an article in the January edition of the journal p...
...ween life and death, suffering an extremely rare c...res //a double kidney transplant, which will give ...tely have the perfect match, so they will be donat... for your children. But now things are looking ver...
...wealth to consider alloting specific funds for r...y under the jurisdiction of the state governments... conference, he said that , the measure was essent...h the proposal to federal Health Minister Tony Abb...
Other Medicine News:Health News:Infants have better iron reserves if umbilical cord clamping is delayed 2Health News:Infants have better iron reserves if umbilical cord clamping is delayed 3Health News:Afro American Women at a High Risk of HPV and Hence Should Be Vaccinated 2
McPherson Speculum
Storz Twisted Snare Wire
Thorton Fixation Ring 16 mm
McNeil-Goldman Scleral and Blepharostat Ring
Medicine Products: